Preterm Labor Treatment Market: By Drugs (Tocolytic Drugs (Beta – Mimetic, Calcium Channel Blockers, NSAIDS), Corticosteroids, Magnesium Sulphate, Antibiotics, Others)), By Dosage Form (Tablets, Capsules, Injections), By End User (Hospitals, Pediatric and Neonatal Clinics, Nursing Homes, Pharmacy) and Geography    

Purchase Option

$ 4400
$ 6600
$ 8900

Preterm Labor Treatment Market was valued at USD 943.1 million in 2022 and is expected to grow at 5.5% CAGR from 2023 to 2029 owing to the increased number of teen and old-aged pregnancies and increased pregnancy rates of twins, triplets, or other multiples because of IVF and other fertility treatments. Preterm labor treatments include medications to prevent labor contractions in the opening of the cervix after week 20 and before week 37 of pregnancy. The preterm labor induces greater health risks for the baby and mother. According to WHO, 13.4 million babies were born preterm in 2020 and preterm birth complications are the leading cause of death among children under 5 years of age, responsible for approximately 900,000 deaths in 2019. The increased prevalence of genital infections, and chronic conditions such as diabetes, and high blood pressure are the major factors driving the preterm labor treatment market.

Moreover, the increased frequency of issues like shortened cervix, problems with the uterus or placenta, and amniotic fluid infections are blooming the market. Furthermore, the recent discovery of Piezo 1 protein in the muscular layer of the uterus for relaxing the uterus has provided an opportunity for the development of a new target for therapies to treat preterm labor. The changing lifestyle with unhealthy eating habits and drinking and smoking have increased the chances of preterm labor. For instance, according to CDC in 2016, the prevalence of smoking was higher around 18.9% in mothers aged between 20 and 29 and 5.2% in mothers aged between 30 and 34. Based on the drugs, tocolytic drugs are dominating the market owing to the extended delay in labor. For instance, as per the report published by Cochrane in August 2022, tocolytics postpone preterm delivery and give women more time to get medications that can assist a baby to breathe and feed if they are born prematurely, and that reduces the likelihood that the child will have cerebral palsy. But, the changing preference of the population to remain childless or adopt a child rather than undergo a complicated pregnancy is hindering the growth of the preterm labor treatment market. However, growing urbanization, improving healthcare infrastructure, high disposable income, and increased awareness among people regarding pregnancies are leading to the flourishment of the market and are expected to burgeon the market in forecasted years.

Preterm Labor Treatment Market Key Developments:

  • In February 2023, Eylea® (aflibercept) injection of Regeneron Pharmaceuticals, Inc. was approved as the first pharmacologic treatment for preterm infants with retinopathy of prematurity (ROP) by the FDA
  • In July 2021, Organon and ObsEva entered a global license agreement to develop and commercialize Ebopiprant (OBE022), an Investigational Agent being evaluated as a first-in-class treatment for preterm labor.

Preterm Labor Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.50%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Preterm Labor Treatment Market Dynamics

Increase in premature birth cases and rapid increase birthrate are major driving factors of preterm labor treatment market. As per WHO statistics, every year 15Mn babies are born. Increase in technological advancements, increasing demand for preterm therapeutics and diagnostics, increase in support of government, increase in R&D investments by market players are expected to propel the growth of preterm labor treatment market. However, lack of awareness, stringent regulatory framework, high costs associated with the treatment will hamper the growth of preterm labor treatment market.

Preterm Labor Treatment Market Segmentation

By Drug
  • Tocolytic Drugs
  • Beta – Mimetic
  • Calcium Channel Blockers
  • NSAIDS
  • Corticosteroids
  • Magnesium Sulphate
  • Antibiotics
  • Others
By Dosage Form
  • Tablets
  • Capsules
  • Injection
By End User
  • Hospitals
  • Pediatric and Neonatal Clinics
  • Nursing Homes
  • Pharmacy
By Geography
  • Latin America
  • North America
  • Asia Pacific
  • Middle East and Africa
  • Europe

Frequently Asked Questions

The preterm labor treatment market size was valued at USD 943.1 million in 2022

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

Pfizer (U.S.) Novartis (Switzerland) Merck & Co (U.S.) Sanofi (France) Johnson & Johnson (U.S.) GlaxoSmithKline (UK)

Key Features of the Reports

  • The preterm labor treatment market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
1. Executive Summary
2.  Global Preterm Labor Treatment Market Introduction 
2.1. Global Preterm Labor Treatment Market  - Taxonomy
2.2. Global Preterm Labor Treatment Market  - Definitions
2.2.1. By Drug
2.2.2. By Dosage Form
2.2.3. By End User
2.2.4. By Region
3. Global Preterm Labor Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Key Developments
4. Global Preterm Labor Treatment Market  By Drug, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
4.1. Tocolytic Drugs
4.1.1. Beta – Mimetic
4.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.1.1.3. Market Opportunity Analysis 
4.1.2. Calcium Channel Blockers
4.1.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.1.2.3. Market Opportunity Analysis 
4.1.3. NSAIDS
4.1.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.1.3.3. Market Opportunity Analysis 
4.2. Corticosteroids
4.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.2.3. Market Opportunity Analysis 
4.3. Magnesium Sulphate
4.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.3.3. Market Opportunity Analysis 
4.4. Antibiotics
4.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.4.3. Market Opportunity Analysis 
4.5. Others
4.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.5.3. Market Opportunity Analysis 
5. Global Preterm Labor Treatment Market  By Dosage Form, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Tablets
5 1 1  Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Capsules
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Injections
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6. Global Preterm Labor Treatment Market  By End User, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Hospitals
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Pediatric and Neonatal Clinics 
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Nursing Homes
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Pharmacy
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7.  Global Preterm Labor Treatment Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Europe
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Asia Pacific
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Latin America
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. MEA
7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
7.6.  Global Preterm Labor Treatment Market - Opportunity Analysis Index, By Dosage Form, Drug, End User,  ,  ,  ,  , and Region, 2023-2029
8. North America Preterm Labor Treatment Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. Drug Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1. Tocolytic Drugs
8.1.1.1. Beta – Mimetic 
8.1.1.2. Calcium Channel Blockers
8.1.1.3. NSAIDS
8.1.2. Corticosteroids
8.1.3. Magnesium Sulphate
8.1.4. Antibiotics
8.1.5. Others
8.2. Dosage Form Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.2.1. Tablets
8.2.2. Capsules
8.2.3. Injections
8.3. End User Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.3.1. Hospitals
8.3.2. Pediatric and Neonatal Clinics 
8.3.3. Nursing Homes
8.3.4. Pharmacy
8.4. Country Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.4.1. USA
8.4.2. Canada
9. Europe Preterm Labor Treatment Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Drug Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1. Tocolytic Drugs
9.1.1.1. Beta – Mimetic 
9.1.1.2. Calcium Channel Blockers
9.1.1.3. NSAIDS
9.1.2. Corticosteroids
9.1.3. Magnesium Sulphate
9.1.4. Antibiotics
9.1.5. Others
9.2. Dosage Form Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1. Tablets
9.2.2. Capsules
9.2.3. Injections
9.3. End User Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1. Hospitals
9.3.2. Pediatric and Neonatal Clinics 
9.3.3. Nursing Homes
9.3.4. Pharmacy
9.4. Country Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1. Germany
9.4.2. France
9.4.3. Italy
9.4.4. Spain
9.4.5. UK
9.4.6. Rest of Europe
10. Asia Pacific Preterm Labor Treatment Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Drug Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1. Tocolytic Drugs
10.1.1.1. Beta – Mimetic 
10.1.1.2. Calcium Channel Blockers
10.1.1.3. NSAIDS
10.1.2. Corticosteroids
10.1.3. Magnesium Sulphate
10.1.4. Antibiotics
10.1.5. Others
10.2. Dosage Form Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1. Tablets
10.2.2. Capsules
10.2.3. Injections
10.3. End User Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1. Hospitals
10.3.2. Pediatric and Neonatal Clinics 
10.3.3. Nursing Homes
10.3.4. Pharmacy
10.4. Country Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1. China
10.4.2. Japan
10.4.3. South Korea
10.4.4. India
10.4.5. Rest of APAC
11. Latin America Preterm Labor Treatment Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Drug Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1. Tocolytic Drugs
11.1.1.1. Beta – Mimetic 
11.1.1.2. Calcium Channel Blockers
11.1.1.3. NSAIDS
11.1.2. Corticosteroids
11.1.3. Magnesium Sulphate
11.1.4. Antibiotics
11.1.5. Others
11.2. Dosage Form Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1. Tablets
11.2.2. Capsules
11.2.3. Injections
11.3. End User Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1. Hospitals
11.3.2. Pediatric and Neonatal Clinics 
11.3.3. Nursing Homes
11.3.4. Pharmacy
11.4. Country Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Argentina
11.4.4. Rest of Latin America
12. MEA Preterm Labor Treatment Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Drug Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1. Tocolytic Drugs
12.1.1.1. Beta – Mimetic 
12.1.1.2. Calcium Channel Blockers
12.1.1.3. NSAIDS
12.1.2. Corticosteroids
12.1.3. Magnesium Sulphate
12.1.4. Antibiotics
12.1.5. Others
12.2. Dosage Form Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1. Tablets
12.2.2. Capsules
12.2.3. Injections
12.3. End User Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1. Hospitals
12.3.2. Pediatric and Neonatal Clinics 
12.3.3. Nursing Homes
12.3.4. Pharmacy
12.4. Country Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of MEA
13.  Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Pfizer (U.S.)
13.2.2. Novartis (Switzerland)
13.2.3. Merck & Co (U.S.)
13.2.4. Sanofi (France)
13.2.5. Johnson & Johnson (U.S.)
13.2.6. GlaxoSmithKline (UK)
13.2.7. AstraZeneca (UK)
13.2.8. Cipla (India)
14.  Research Methodology
15.  Key Assumptions and Acronyms
  • Pfizer (U.S.)
  • Novartis (Switzerland)
  • Merck & Co (U.S.)
  • Sanofi (France)
  • Johnson & Johnson (U.S.)
  • GlaxoSmithKline (UK)
  • AstraZeneca (UK)
  • Cipla (India)

Adjacent Markets